In 2020, the Washington State Legislature enacted Engrossed Substitute Senate Bill (ESSB) 6404 (Chapter 316, Laws of 2020, codified at RCW 48.43.0161), which requires that health carriers with at least one percent of the market share in Washington State annually report certain aggregated and de-identified data related to prior authorization to the Office of the Insurance Commissioner (OIC). Prior authorization is a utilization review tool used by carriers to review the medical necessity of requested health care services for specific health plan enrollees. Carriers choose the services that are subject to prior authorization review. The reported data includes prior authorization information for the following categories of health services:
• Inpatient medical/surgical
• Outpatient medical/surgical
• Inpatient mental health and substance use disorder
• Outpatient mental health and substance use disorder
• Diabetes supplies and equipment
• Durable medical equipment
The carriers must report the following information for the prior plan year (PY) for their individual and group health plans for each category of services:
• The 10 codes with the highest number of prior authorization requests and the percent of approved requests.
• The 10 codes with the highest percentage of approved prior authorization requests and the total number of requests.
• The 10 codes with the highest percentage of prior authorization requests that were initially denied and then approved on appeal and the total number of such requests.
Carriers also must include the average response time in hours for prior authorization requests and the number of requests for each covered service in the lists above for:
• Expedited decisions.
• Standard decisions.
• Extenuating-circumstances decisions.
Engrossed Second Substitute House Bill 1357 added additional prescription drug prior authorization reporting requirements for health carriers beginning in reporting year 2024. Carriers were provided the opportunity to submit voluntary prescription drug prior authorization data for the 2023 reporting period. Prescription drug reporting was required for the 2024 reporting period.